Submission

1. Triple negative myeloproliferations (absence of JAK2, CALR and MPL mutations) interrogating the borderline between myeloproliferative neoplasms and non-neoplastic proliferations, as well as “borderline” to MDS/MPN and MDS with thrombocytosis (including cases that display an MPN-like clinical and morphological presentation, but MDS and MDS/MPN-like genetics: 5q-, SF3B1, TET2, SRSF2, ZRSR2, etc.). Cases with germline variants, as well as cases with well-defined secondary causes (e.g. hereditary or secondary polycythaemia), are excluded.

2. Acute myeloid leukaemia and MDS cases with potentially disease-defining mutations that are not yet recognised as such in the current classification systems (e.g. RUNX1, UBTF, etc.).

3. Primary large cell / high-grade lymphomas of bone or presenting exclusively in the bone marrow.